Both in Pharmaceuticals
Upstream Bio vs Keros Therapeutics
Over the past year UPB returned −86.8% and KROS returned −22.9%; their daily moves had a correlation of 0.30.
UPB −86.8% KROS −22.9%Growth of $1, one year, split-adjusted
| Metric | UPB | KROS |
|---|---|---|
| Price | $2.76 | $10.66 |
| Market cap | $151.2M | $211.4M |
| Today | −18.10% | −3.96% |
| 1 month | −48.0% | −6.2% |
| 6 months | −72.4% | −8.7% |
| Year to date | −89.8% | −47.6% |
| 1 year | −87.3% | −26.4% |
| Revenue growth (YoY) | −17.5% | −100.0% |
| Gross margin | 100.0% | — |
| Net margin | −5136.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 47.9× | 14.1× |
| Net cash | $261.3M | $257.6M |
| Dividend yield | — | — |
| Volatility (60d) | 76.9% | 45.5% |
| Short % of float | 13.3% | 6.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).